Jordan Denise Kelly, PT, DPT Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 7 Riverwoods Dr, Exeter, NH 03833 Phone: 603-772-4700 |
Gloria Everett, Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 5 Sloans Brook Dr, Exeter, NH 03833 Phone: 781-608-4988 |
Lisa A Woodman, PT Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 187a High St, Exeter, NH 03833 Phone: 603-772-0708 Fax: 603-772-3491 |
Richard O Feeney, Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 7 Alumni Dr, Exeter, NH 03833 Phone: 603-777-1000 Fax: 603-777-1001 |
Dr. Daniel Sherwin Zipin, D.O. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 7 Alumni Dr, Exeter, NH 03833 Phone: 603-777-1000 Fax: 603-777-1001 |
News Archive
Older adults who are classified as having "prediabetes" due to moderately elevated measures of blood sugar usually don't go on to develop full-blown diabetes, according to a study led by researchers at Johns Hopkins Bloomberg School of Public Health.
Elsevier, the world's leading publisher of scientific, technical and medical (STM) information products and services announced today that it is publicly sharing its internal custom publication guidelines so that the scientific and medical communities can have insight into a new and practical set of publishing standards for producing custom and sponsored publications.
Alnara Pharmaceuticals, Inc., a pharmaceutical company developing novel, non-systemic orally-delivered protein therapeutics for the treatment of metabolic diseases, announced today that results from a landmark, international Phase 3 study of the long-term safety and nutritional benefits of liprotamase for the treatment of pancreatic insufficiency in patients with cystic fibrosis (CF) will be presented at the 23rd Annual North American Cystic Fibrosis Conference (NACFC) being held October 15-17, 2009 in Minneapolis, Minnesota.
Biotel Inc. announced results for its first quarter ended September 30, 2009 with net earnings of $128,000, or $0.04 per diluted share, on revenues of $3,263,000. This compares to net earnings of $328,000, or $0.11 per diluted share, on revenues of $3,168,000 for the first quarter of last year.
Abbott and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry instrument platform, specifically the company's i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine's intellectual property related to galectin-3.
› Verified 4 days ago